Prévost Jérémie, Gasser Romain, Beaudoin-Bussières Guillaume, Richard Jonathan, Duerr Ralf, Laumaea Annemarie, Anand Sai Priya, Goyette Guillaume, Benlarbi Mehdi, Ding Shilei, Medjahed Halima, Lewin Antoine, Perreault Josée, Tremblay Tony, Gendron-Lepage Gabrielle, Gauthier Nicolas, Carrier Marc, Marcoux Diane, Piché Alain, Lavoie Myriam, Benoit Alexandre, Loungnarath Vilayvong, Brochu Gino, Haddad Elie, Stacey Hannah D, Miller Matthew S, Desforges Marc, Talbot Pierre J, Maule Graham T Gould, Côté Marceline, Therrien Christian, Serhir Bouchra, Bazin Renée, Roger Michel, Finzi Andrés
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Cell Rep Med. 2020 Oct 20;1(7):100126. doi: 10.1016/j.xcrm.2020.100126. Epub 2020 Sep 30.
SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）导致了2019冠状病毒病（COVID-19）大流行，感染了数百万人并造成数十万人死亡。SARS-CoV-2的刺突糖蛋白介导病毒进入细胞，是中和抗体的主要靶标。了解针对SARS-CoV-2的抗体反应对于疫苗、治疗方法和公共卫生干预措施的开发至关重要。在此，我们对106名感染SARS-CoV-2的个体进行了一项横断面研究，以评估针对SARS-CoV-2刺突蛋白的体液反应。大多数感染个体在症状出现后2周内产生抗刺突蛋白抗体。受体结合域（RBD）特异性免疫球蛋白G（IgG）水平随时间持续存在，抗RBD IgM水平在症状缓解后下降。虽然大多数个体在感染后2周内产生中和抗体，但中和活性水平随时间显著下降。我们的结果凸显了研究自然感染SARS-CoV-2后中和活性持久性的重要性。
